Rayno Biopharmaceuticals Portfolio in a Biotech Bull Market

Biotech Bull Market 2017 Performance as of 9/5/17

Rayno Biopharmaceutical Portfolio outperforms the market.

XBI was the Best Play up 41.88% YTD.

Biotech stocks broke through the July sector highs as tracked by major ETFs. However we are still about 25% off the July 2015 bubble highs but supported by good earnings fundamentals, strong technicals and potentially a seasonal strong Q4. This leg of the new biotech bull market began in January 2017 after a vicious Q4 2015 sell-off.

  • Once again our portfolio model shows that for the average biotech investor one or two ETFs are a good choice.
  • The XBI continues to be the leader up over 41% YTD despite greater volatility. We recommended XBI in January at a price of $64.
  • Most of our large caps picks did well but the IBB did better up 25.5% YTD.
  • Our more speculative small cap picks did extremely well with bluebird bio (BLUE), a CAR-T play, up 103.3% and Foundation Medicine (FMI) an emerging leader in personalized cancer treatment, up 127.4%.
  • M&A proved to be a strong driver with the acquisition of Kite Pharma (KITE) by Gilead Sciences (GILD).
Company Ticker Date Price Price Perf 9/5 Perf %
Started 4/25 % P YTD
Abbvie ABBV 2/3/16 56.5 65.45 16 75.25 20.12
Amgen AMGN 9/12/16 172 165 -4 176.74 20.88
Biogen BIIB 2/13/17 275 286.5 4.5 315.83 11.37
bluebird bio BLUE 2/3/16 43.75 88.1 103 125.45 103.3
Bristol Myers BMY 2/16/16 61 54.2 -7.7 59.81 2.36
Foundation Med FMI 7/5/16 20.4 34 68 40.25 127.4
Gilead Sci GILD 2/3/16 85.8 67.3 -20.9 82.56 15.29
Roche ADR RHHBY 4/4/16 30.36 32.4 7.9 31.65 10.94
IBB 6/29/16 250 296 18.4 333.04 25.5
XBI 1/31/17 64 70.7 9.4 83.98 41.88
QQQ

(reference)

n/a 135.13 n/a 144.69 22.12
FBIOX (reference)
227.81 24.5

, , , ,

No comments yet.

Leave a Reply